Sutro Biopharma, Inc. (STRO) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 24.82 |
| Open | 25.71 |
| Day High | 25.71 |
| Day Low | 23.77 |
| 52-Week High | 43.85 |
| 52-Week Low | 7.15 |
| Volume | 163,209 |
| Average Volume | 351,585 |
| Market Cap | 233.9M |
| PE | -1.6 |
| EPS | -15.07 |
| Moving Average 50 Days | 27.64 |
| Moving Average 200 Days | 20.71 |
| Change | -0.65 |
Sutro Biopharma Announces Participation at the 16th World ADC London Summit
GlobeNewswire Inc.
Feb 23, 2026 1:30 PM GMT
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced
Sutro Biopharma Announces Pricing of $110.0 million Underwritten Offering
GlobeNewswire Inc.
Feb 10, 2026 12:00 PM GMT
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (Nasdaq: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced
Sutro Biopharma to Present at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 07, 2026 9:05 PM GMT
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced